

Intiva BioPharma Files a U.S. Patent Application for the Use of Cannabinoids for Improving Sexual Health

Sexual health, sometimes referred to as sexual dysfunction, is a major issue because it affects both males and females.

DENVER, CO , UNITED STATES, July 20, 2017 /EINPresswire.com/ -- [INTIVA BioPharma](#) Inc. has filed a provisional patent application with the United States Patent Office describing methods and compositions for improving sexual health. The methods comprise the administration of a composition comprising one or more cannabinoids and/or one or more terpenes.

Sexual health is a major topic of discussion and research because it affects both males and females. Sexual health issues, sometimes termed sexual dysfunction, may be the result of organic issues, psychological issues or a combination of both.

Examples of organic issues include vascular diseases, such as those associated with hypertension or diabetes mellitus, prescription medication, and/or by psychiatric disease such as depression.

Examples of psychological factors include fear, performance anxiety, and interpersonal conflict. Sexual health issues and sexual dysfunction issues, in particular, may impair sexual performance, diminish self-esteem and disrupt personal relationships thereby inducing personal distress.

Male sexual health issues or dysfunction issues include male erectile dysfunction, ejaculatory disorders, such as premature ejaculation, anorgasmia (inability to achieve orgasm) and desire disorders such as hypoactive sexual desire disorder (lack of interest in sex).

Female sexual health issues or dysfunction issues include genitopelvic pain/penetration disorders, sexual interest/arousal disorders, and female orgasmic disorders.

Robert Goldfarb, COO of INTIVA BioPharma, stated, "Due to the scope of male and female health issues, there is a need for improvements in the treatments." He further stated, "For both men and women anecdotal evidence suggests benefits in using cannabinoids and/or terpenes for improving



sexual health. We're hopeful that our pre-clinical and clinical pathway will lead to one or more medicines that improve conditions affecting male and female sexual health."

INTIVA BioPharma has assembled a team of experienced professionals in pharmaceutical development and regulatory compliance for its drug development activities.

About INTIVA BioPharma Inc.

INTIVA BioPharma is proceeding with pre-clinical and clinical drug development activities, in accordance with U.S. Food and Drug Administration ("FDA") protocols, for a number of pharmaceutical formulations that include cannabinoids.

BioPharma's drug development strategy consists of:

The determination of medical conditions and disorders that could potentially benefit from cannabinoid-based formulations;

Conducting "freedom to operate" investigations on these conditions;

The preparation of patent applications and the prosecution of such application and/or the licensing of existing patents;

Identifying the regulatory pathway with the U.S. Food and Drug Administration (FDA); and

Proceeding with pre-clinical and clinical development activities in accordance with FDA protocols for submission to obtain approval for the particular product(s).

INTIVA Disclosure Notice: This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained herein or which are otherwise made by or on behalf of the Company that are not statements of historical facts may be deemed forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "to," "plan," "expect," "believe," "anticipate," "intend," "could," "should," "would," "estimate," or "continue," or the negative or other variations thereof or comparable terminology are intended to identify forward-looking statements. Readers are cautioned that all forward-looking statements involve risk and uncertainties which may cause results to differ materially from those set forth in the statements. Such risks and uncertainties include, but are not limited to the following: the success of research and development activities and the speed with which regulatory authorizations and product launches may be achieved; government regulation generally; competitive developments; the ability to successfully market products domestically and internationally; difficulties or delays in manufacturing or issues relating to manufacturing capacity; commercial obstacles to the successful introduction of brand products generally; legal defense costs, insurance expenses, settlement costs, and the risk of an adverse decision or settlement relating to product liability, patent protection, governmental investigations, and other legal proceedings; the Company's ability to acquire and protect patents and other intellectual property both domestically and internationally; the absence of certainty regarding the receipt of required regulatory approval or the timing or terms of such approvals; any changes in business, political and economic conditions; business interruption due to hurricanes or other events outside of the Company's control.

Readers are cautioned not to place reliance on these forward-looking statements, which are valid only as of the date they were made. The Company undertakes no obligation to update or revise any forward-looking statements to reflect new information or the occurrence of unanticipated events or otherwise, except as expressly required by law.

Contact

Jeffrey Friedland
Chief Executive Officer
INTIVA BioPharma Inc.
Tel. 1-800-497-2915
Email IntivaBioPharma@intiva.us
Website www.INTIVABioPharma.com

Jeffrey Friedland
INTIVA Biopharma Inc.
6464508909
email us here

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2017 IPD Group, Inc. All Right Reserved.